Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important Principles

By using the website www.bellevue-am.uk, you confirm that you have read, understood and accepted the general information provided by the Bellevue Group AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

For a full explanation of risks and the overall risk profile of financial products mentioned on this site, please refer to the relevant Key Investor Information Documents (KIDs) and Prospectuses.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions. Alternatively, you can select "I don't accept" if you wish to leave the website.

This website uses cookies, which are necessary for the technical operation of the website and which are always set. Other cookies to personalize content and analyze access to our website are only set with your consent. We also share information about your use of our website with our social media, advertising and analytics partners.

Our core competence – Healthcare Investing

25 years experience - 22 healthcare experts - GBP 8.3 bn
With 22 experts we are specialist in healthcare investing with the broadest range of innovative healthcare strategies in Europe managing assets of GBP 7.1 bn in this section. BB Biotech has been a leader in Biotech investing for over 25 years. In addition, BB Healthcare strategy offer both closed ended and open ended solutions for active investments in the global healthcare sector. 

Committed to active asset management

We pursue a high conviction approach and have benchmark independent, fundamental bottom-up driven investment style. Our employees are both investment experts and entrepreneurs, and they have a stake in the success of their own clients. This culture goes hand in hand with a strong conviction in active management with a high degree of discipline. Bellevue’s basic business philosophy gives the portfolio management teams the entrepreneurial freedom they need to deliver what we promise. There are no high-level investment committees or CIOs. All of our expert teams within the various product areas, which operate independently, are distinguished by a high degree of responsibility, respect and visionary leadership. This has kept us and our clients one step ahead of the broader investment community since 1993.

Board of Directors

As a healthcare investment manager, we create attractive returns and performance for our clients.

  • Member of the Board

    Member of the Board

    Paul Major

    Paul has 26 years of experience in the healthcare sector on the sell-side and was top-rated by a number of institutional investment clients. He was one of the first research partners at Redburn. His work there included bespoke projects on healthcare portfolio construction for several institutions. Paul was previously an analyst and corporate financier at UBS Warburg and studied biochemistry.

  • Member of the Board

    Member of the Board

    Martin Gubler

    Martin Gubler worked thirteen years at PricewaterhouseCoopers AG and nine years at St. Galler Kantonalbank AG. He joined Bellevue Asset Management in 2019 as CFO, COO and CRO. Martin Gubler is a Swiss Certified Public Accountant and Swiss-certified banking expert with Federal Diploma.

  • Member of the Board

    Member of the Board

    Claude Mikkelsen

    Claude Mikkelsen is Director Investor Relations for BB Biotech. Before that, he served as interim Finance Director at Ecron Acunova after his position as Senior Vice President Finance & Investor Relations at Pharmexa. Claude Mikkelsen has a master’s degree in Economics and Law from Aalborg University and has studied at INSEAD in France.

  • Non-Executive Director

    Non-Executive Director

    Dr. Daniel Sigg

    Daniel Sigg held various senior management positions in asset management and consulting. As Global Head at UBS, Daniel Sigg was responsible for institutional asset management before joining the board of Times Square Capital Management in New York in 2000. Today, he is active in financial advisory services as a Principal of DHS International Advisors LLC. In 2007, he joined the Board of Directors of Bellevue Group. 

Explore Bellevue